Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“Assessment Tumour response was defined using European Organization for Research and Treatment of Cancer Response Evaluation Criteria In Solid Tumours (EORTC-RECIST) criteria version 1.1 (Eisenhauer et al. 2009).”
MethodInfluentialEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,715 · cited 9×
“%) are not good candidates to surgical treatment (Tomlinson et al. 2007; Adam et al. 2012; Clancy et al. 2014; Fong et al. 1999), and only 10–30 % can be converted to a resectable state with chemotherapy (Adam et al. 2009; Quan et al. 2012; Leonard et al. 2005).”
BackgroundInfluentialActual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure
Tomlinson, J. S., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kornprat, P., Gonen, M., Kemeny, N., Brennan, M. F., Blumgart, L. H., & D'Angelica, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0833 · Cited by 1,187 · cited 5×
“Tomlinson (Tomlinson et al. 2007) reported a 99 % long-term cancer-specific survival in 102 patients with colorectal liver metastases surviving ≥10 years after resection, suggesting the achievement of cure in this subset of oligometastatic patients.”
BackgroundInfluentialMulti-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases
Rusthoven, K. E., Kavanagh, B. D., Burri, S. H., Chen, C., Cardenes, H., Chidel, M. A., Pugh, T. J., Kane, M., Gaspar, L. E., & Schefter, T. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6386 · Cited by 1,082 · cited 6×
“While Rusthoven (Rusthoven et al. 2009), with a prescription dose of 60 Gy in 3 fractions, showed a decrease of LC for lesions >3 cm in diameter, our results have shown that LC is not correlated with the size of the lesions (less or larger than 3 cm in diameter), when a higher prescription dose is…”
BackgroundResultInfluentialHepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history
Scheele, J., Stangl, R., & Altendorf-Hofmann, A. (1990) · Journal of British Surgery · doi:10.1002/bjs.1800771115 · Cited by 836 · cited 1×
“Thirty to 70 % of these patients will develop liver metastases, often isolated or associated with limited metastatic foci of disease (Yoon and Tanabe 1999; Scheele et al. 1990).”
BackgroundMulti-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
Rusthoven, K. E., Kavanagh, B. D., Cardenes, H., Stieber, V. W., Burri, S. H., Feigenberg, S. J., Chidel, M. A., Pugh, T. J., Franklin, W., Kane, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6329 · Cited by 805 · cited 6×
“While Rusthoven (Rusthoven et al. 2009), with a prescription dose of 60 Gy in 3 fractions, showed a decrease of LC for lesions >3 cm in diameter, our results have shown that LC is not correlated with the size of the lesions (less or larger than 3 cm in diameter), when a higher prescription dose is…”
BackgroundResultInfluentialAnalysis of radiation-induced liver disease using the Lyman NTCP model
Dawson, L. A., Normolle, D., Balter, J. M., McGinn, C. J., Lawrence, T. S., & Ten Haken, R. K. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02846-8 · Cited by 767 · cited 1×
“This technique allows to overcome liver tissue low tolerance to irradiation and to avoid the radiation-induced liver disease (RILD), which can result in liver failure and death (Dawson et al. 2002).”
BackgroundExtracranial Stereotactic Radioablation *
Timmerman, R., Papiez, L., McGarry, R., Likes, L., DesRosiers, C., Frost, S., & Williams, M. (2003) · Chest · doi:10.1378/chest.124.5.1946 · Cited by 671 · cited 3×
“In recent years, several studies have been performed about SBRT, mostly including patients with inoperable stage I non-small cell lung cancer and oligometastatic diseases (Timmerman et al. 2003; Alongi et al. 2012).”
BackgroundPatients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?
Adam, R., Wicherts, D. A., de Haas, R. J., Ciacio, O., Lévi, F., Paule, B., Ducreux, M., Azoulay, D., Bismuth, H., & Castaing, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9273 · Cited by 590 · cited 7×
“The introduction of modern chemotherapy regimens in the current treatment for colorectal liver metastases has improved median overall survival (OS), although local control (LC) rates are still unsatisfactory (Biasco et al. 2006; Saltz 2005; Adam et al. 2009; Quan et al. 2012).”
BackgroundInfluentialAdam, R., De Gramont, A., Figueras, J., Guthrie, A., Kokudo, N., Kunstlinger, F., Loyer, E., Poston, G., Rougier, P., Rubbia-Brandt, L., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0121 · Cited by 583 · cited 6×
“%) are not good candidates to surgical treatment (Tomlinson et al. 2007; Adam et al. 2012; Clancy et al. 2014; Fong et al. 1999), and only 10–30 % can be converted to a resectable state with chemotherapy (Adam et al. 2009; Quan et al. 2012; Leonard et al. 2005).”
BackgroundInfluentialPhase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases
Lee, M. T., Kim, J. J., Dinniwell, R., Brierley, J., Lockwood, G., Wong, R., Cummings, B., Ringash, J., Tse, R. V., Knox, J. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0600 · Cited by 473 · cited 4×
“In recent years, SBRT has also been investigated for the treatment of inoperable liver metastases, with encouraging results on LC and OS (Alongi et al. 2012; Dawson and Lawrence 2004; Herfarth and Debus 2005; Katz et al. 2007; Lee et al. 2009; Scorsetti et al. 2013; Rusthoven et al. 2009; Corbin et al. 2013; Ambrosino…”
BackgroundInfluentialPhase II study on stereotactic body radiotherapy of colorectal metastases
Hoyer, M., Roed, H., Traberg Hansen, A., Ohlhuis, L., Petersen, J., Nellemann, H., Kiil Berthelsen, A., Grau, C., Aage Engelholm, S., & Von Der Maase, H. (2006) · Acta Oncologica · doi:10.1080/02841860600904854 · Cited by 426 · cited 3×
“Hoyer (Hoyer et al. 2006) treated 44 patients with small colorectal liver metastases with 1- and 2-year LC rates of 90 and 78 %, respectively.”
BackgroundRadiation as an immunological adjuvant: current evidence on dose and fractionation
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00153 · Cited by 332 · cited 1×
“Phenomenological elements, the patterns-of-failure concept, the theory of oligometastases as an intermediate and potentially curative state, the Norton–Simon hypothesis, and the impact of immune-modulation are some of the instruments applied in the rationale (Demaria and Formenti 2012).”
MethodDose-Escalation Study of Single-Fraction Stereotactic Body Radiotherapy for Liver Malignancies
Goodman, K. A., Wiegner, E. A., Maturen, K. E., Zhang, Z., Mo, Q., Yang, G., Gibbs, I. C., Fisher, G. A., & Koong, A. C. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.08.020 · Cited by 323 · cited 2×
“In recent years, SBRT has also been investigated for the treatment of inoperable liver metastases, with encouraging results on LC and OS (Alongi et al. 2012; Dawson and Lawrence 2004; Herfarth and Debus 2005; Katz et al. 2007; Lee et al. 2009; Scorsetti et al. 2013; Rusthoven et al. 2009; Corbin et al. 2013; Ambrosino…”
BackgroundLeonard, G. D., Brenner, B., & Kemeny, N. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.349 · Cited by 314 · cited 4×
“%) are not good candidates to surgical treatment (Tomlinson et al. 2007; Adam et al. 2012; Clancy et al. 2014; Fong et al. 1999), and only 10–30 % can be converted to a resectable state with chemotherapy (Adam et al. 2009; Quan et al. 2012; Leonard et al. 2005).”
BackgroundInfluentialStereotactic body radiotherapy for colorectal liver metastases: A pooled analysis
Chang, D. T., Swaminath, A., Kozak, M., Weintraub, J., Koong, A. C., Kim, J., Dinniwell, R., Brierley, J., Kavanagh, B. D., Dawson, L. A., et al. (2011) · Cancer · doi:10.1002/cncr.25997 · Cited by 302
Gillams, A. R., & Lees, W. R. (2009) · European Radiology · doi:10.1007/s00330-008-1258-5 · Cited by 254 · cited 4×
“Gillams (Gillams and Lees 2009) and Siperstein (Siperstein et al.”
BackgroundInfluentialSurvival After Radiofrequency Ablation of Colorectal Liver Metastases: 10-Year Experience
Siperstein, A. E., Berber, E., Ballem, N., & Parikh, R. T. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e318155a7b6 · Cited by 240 · cited 6×
“Gillams (Gillams and Lees 2009) and Siperstein (Siperstein et al. 2007) Ta bl e 5 R es ul ts o f cu rr en t s tu di es o n SB R T f or c ol or ec ta l l iv er m et as ta se s a H oy er e t a l. an d C ha ng e t a l. re po rt ed p ro gr es si on to g ra de 2 a nd h ig he r m or bi di ty s co re s A…”
BackgroundInfluentialHypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases
Katz, A. W., Carey-Sampson, M., Muhs, A. G., Milano, M. T., Schell, M. C., & Okunieff, P. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.10.025 · Cited by 232 · cited 4×
“In recent years, SBRT has also been investigated for the treatment of inoperable liver metastases, with encouraging results on LC and OS (Alongi et al. 2012; Dawson and Lawrence 2004; Herfarth and Debus 2005; Katz et al. 2007; Lee et al. 2009; Scorsetti et al. 2013; Rusthoven et al. 2009; Corbin et al. 2013; Ambrosino…”
BackgroundInfluentialReview and Uses of Stereotactic Body Radiation Therapy for Oligometastases
Alongi, F., Arcangeli, S., Filippi, A. R., Ricardi, U., & Scorsetti, M. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0092 · Cited by 209 · cited 5×
“…stereotactic body radiation therapy (SBRT) has developed as a system for delivering a conformal high dose of radiation to the tumour and a minimal dose to surrounding critical tissues, with a hypofractionation schedule, and has been used in several sites (Timmerman et al. 2003; Alongi et al. 2012).”
BackgroundInfluentialSelf-citationPhase I Dose-Escalation Study of Stereotactic Body Radiotherapy in Patients With Hepatic Metastases
Rule, W., Timmerman, R., Tong, L., Abdulrahman, R., Meyer, J., Boike, T., Schwarz, R. E., Weatherall, P., & Chinsoo Cho, L. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1405-5 · Cited by 209 · cited 3×
“5 weeks (Rule et al. 2011) but on a cohort of miscellaneous primary tumours.”
BackgroundInfluentialScorsetti, M., Arcangeli, S., Tozzi, A., Comito, T., Alongi, F., Navarria, P., Mancosu, P., Reggiori, G., Fogliata, A., Torzilli, G., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.021 · Cited by 189 · cited 4×
“…liver metastases, with encouraging results on LC and OS (Alongi et al. 2012; Dawson and Lawrence 2004; Herfarth and Debus 2005; Katz et al. 2007; Lee et al. 2009; Scorsetti et al. 2013; Rusthoven et al. 2009; Corbin et al. 2013; Ambrosino et al. 2009; Goodman et al. 2010; Kavanagh et al. 2008).”
BackgroundMethodInfluentialSelf-citationExtracranial Oligometastases: A Subset of Metastases Curable With Stereotactic Radiotherapy
Corbin, K. S., Hellman, S., & Weichselbaum, R. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9651 · Cited by 185 · cited 4×
“In recent years, SBRT has also been investigated for the treatment of inoperable liver metastases, with encouraging results on LC and OS (Alongi et al. 2012; Dawson and Lawrence 2004; Herfarth and Debus 2005; Katz et al. 2007; Lee et al. 2009; Scorsetti et al. 2013; Rusthoven et al. 2009; Corbin et al. 2013; Ambrosino…”
BackgroundInfluentialRadiofrequency ablation in the treatment of liver metastases from colorectal cancer
Cirocchi, R., Trastulli, S., Boselli, C., Montedori, A., Cavaliere, D., Parisi, A., Noya, G., & Abraha, I. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006317.pub3 · Cited by 179 · cited 3×
“…is the treatment of choice, but presents some limitations in the presence of lesions larger than 3 cm of diameter or in proximity of major blood vessels, the main biliary tract or the gallbladder, or just beneath the diaphragm (Cirocchi et al. 2012; Gillams and Lees 2009; Siperstein et al. 2007).”
BackgroundStereotactic body radiation therapy for colorectal liver metastases
van der Pool, A. E. M., Méndez Romero, A., Wunderink, W., Heijmen, B. J., Levendag, P. C., Verhoef, C., & IJzermans, J. N. M. (2010) · British Journal of Surgery · doi:10.1002/bjs.6895 · Cited by 172 · cited 2×
“Van der Pool (van der Pool et al. 2010) published data on 20 patients and 31 lesions with a LC rate at 1 and 2 years of 100 and 74 %, respectively.”
BackgroundStereotactic body radiation therapy for colorectal liver metastases
Mohamad, I., Barry, A. S., Dawson, L. A., & Hosni, A. (2022) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1923836 · Cited by 145
Clancy, C., Burke, J. P., Barry, M., Kalady, M. F., & Coffey, J. C. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3805-4 · Cited by 134 · cited 6×
“%) are not good candidates to surgical treatment (Tomlinson et al. 2007; Adam et al. 2012; Clancy et al. 2014; Fong et al. 1999), and only 10–30 % can be converted to a resectable state with chemotherapy (Adam et al. 2009; Quan et al. 2012; Leonard et al. 2005).”
BackgroundInfluentialQuan, D., Gallinger, S., Nhan, C., Auer, R. C., Biagi, J. J., Fletcher, G. G., Law, C., Moulton, C.-A. E., Ruo, L., Wei, A. C.-C., et al. (2012) · Surgery · doi:10.1016/j.surg.2011.12.018 · Cited by 115 · cited 4×
“%) are not good candidates to surgical treatment (Tomlinson et al. 2007; Adam et al. 2012; Clancy et al. 2014; Fong et al. 1999), and only 10–30 % can be converted to a resectable state with chemotherapy (Adam et al. 2009; Quan et al. 2012; Leonard et al. 2005).”
BackgroundInfluentialTreatment of hepatic metastases from colorectal cancer: Many doubts, some certainties
Biasco, G., Derenzini, E., Grazi, G. L., Ercolani, G., Ravaioli, M., Pantaleo, M. A., & Brandi, G. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.12.011 · Cited by 113 · cited 3×
“The introduction of modern chemotherapy regimens in the current treatment for colorectal liver metastases has improved median overall survival (OS), although local control (LC) rates are still unsatisfactory (Biasco et al. 2006; Saltz 2005; Adam et al. 2009; Quan et al. 2012).”
BackgroundAmbrosino, G., Polistina, F., Costantin, G., Francescon, P., Guglielmi, R., Zanco, P., Casamassima, F., Febbraro, A., Gerunda, G. E., & Lumachi, F. (2009) · PubMed · Cited by 89
The Role of Radiotherapy in the Treatment of Liver Metastases
Dawson, L. A., & Lawrence, T. S. (2004) · The Cancer Journal · doi:10.1097/00130404-200403000-00009 · Cited by 34 · cited 4×
“In recent years, SBRT has also been investigated for the treatment of inoperable liver metastases, with encouraging results on LC and OS (Alongi et al. 2012; Dawson and Lawrence 2004; Herfarth and Debus 2005; Katz et al. 2007; Lee et al. 2009; Scorsetti et al. 2013; Rusthoven et al. 2009; Corbin et al. 2013; Ambrosino…”
BackgroundInfluential
Cited by
Lehrer, E. J., Singh, R., Wang, M., Chinchilli, V. M., Trifiletti, D. M., Ost, P., Siva, S., Meng, M.-B., Tchelebi, L., & Zaorsky, N. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6146 · Cited by 196
Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies
Miller, E. D., Hitchcock, K. E., & Romesser, P. B. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00900-5 · Cited by 31
“Scorsetti et al. performed a phase II trial of patients with inoperable liver metastases not amenable to RFA, treating the tumors with an SBRT dose of 45–78.5 in 3 fractions [39].”
Influential
Metadata
- Authors
- Scorsetti, M., Comito, T., Tozzi, A., Navarria, P., Fogliata, A., Clerici, E., Mancosu, P., Reggiori, G., Rimassa, L., Torzilli, G., Tomatis, S., Santoro, A., & Cozzi, L.
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2014-09-23
- Volume
- 141
- Issue
- 3
- Pages
- 543-553
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- OpenAlex
- W2055407227
- Cited by
- 174
- References
- 32
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.